Topical Targretin and Intralesional Interferon Alfa for Cutaneous Lymphoma of the Scalp | Allergy and Clinical Immunology | JAMA Dermatology | JAMA Network
[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
The Cutting Edge
November 2002

Topical Targretin and Intralesional Interferon Alfa for Cutaneous Lymphoma of the Scalp

Author Affiliations


Arch Dermatol. 2002;138(11):1421-1423. doi:10.1001/archderm.138.11.1421

Report of a case

A 56-year-old man presented with multiple red-violaceous firm, nontender nodules and plaques on the left frontal and parietal areas of his scalp (Figure 1). There was no regional lymphadenopathy. The patient denied any fever or chills. His medical history was significant for diabetes mellitus and hypertension, for which he was taking metformin, troglitazone, glyburide, and enalapril maleate. There was no personal or family history of cancer. A skin biopsy specimen from a scalp lesion showed a dense atypical lymphocytic infiltrate suggestive of malignant lymphoma (Figure 2). Results of extensive investigation including a bone marrow biopsy, lymph node biopsy, and computed tomographic scan of the chest, abdomen, and pelvis were negative for systemic lymphoma. A specimen from a repeated biopsy was submitted for flow cytometric analysis and Southern blotting for B- and T-cell receptor rearrangement. Immunophenotypic analysis showed a mixture of B and T cells. The T cells showed expression of CD3, CD5, and CD7 with markedly reduced and almost absent CD2, while the B cells expressed CD19, CD20, and CD22 with no evidence of surface immunoglobulin light chain restriction (Figure 3). This was suggestive of an atypical T-cell population. There was no T- or B-cell rearrangement on the first Southern blotting examination of the specimen; however, another examination of the specimen, which was submitted for T- and B-cell gene rearrangement analysis with restriction enzymes, demonstrated the presence of a monoclonal B-lymphocyte population indicative of a follicle center B-cell lymphoma. The patient did not want to undergo surgery, radiotherapy, or systemic chemotherapy.

Figure 1. 
Multiple red-violaceous, nontender nodules and plaques on the left frontal and parietal areas of the patient's scalp.

Multiple red-violaceous, nontender nodules and plaques on the left frontal and parietal areas of the patient's scalp.

Figure 2. 
Histologic examination of the scalp lesion showing a dense atypical lymphocytic infiltrate suggestive of malignant lymphoma (hematoxylin-eosin, original magnification ×40).

Histologic examination of the scalp lesion showing a dense atypical lymphocytic infiltrate suggestive of malignant lymphoma (hematoxylin-eosin, original magnification ×40).

Figure 3. 
Immunophenotypic analysis of the scalp lesion showing strong positivity for CD20 (CD20 immunoperoxidase, original magnification ×15).

Immunophenotypic analysis of the scalp lesion showing strong positivity for CD20 (CD20 immunoperoxidase, original magnification ×15).

Therapeutic challenge

The challenge was to find a noninvasive therapy for the patient. The combination of interferon alfa and bexarotene gel (Targretin) appears to be effective in treating primary cutaneous B-cell lymphoma of the scalp.


The patient was initially treated with intralesional injections of triamcinolone (20 mg/mL), and the lesions improved with flattening and decrease in erythema. However, after 5 injections, 1 per month for 5 months, he reached a point where no further improvement was noted. At this time, his treatment was switched to intralesional interferon alfa. He received a total of 10 injections of 5 million units each of interferon alfa at 4-week intervals for 5 months. The patient's condition improved again with flattening of the lesions; however, the patient required monthly injections because the tumors would reappear. Topical bexarotene gel (Targretin, Ligand Pharmaceuticals Inc, San Diego, Calif), applied twice a day, was then added to the regimen. He responded very well to the combination and, within 2 months, the lesions were completely flat with no clinical evidence of recurrence (Figure 4). The patient has been applying the Targretin gel on an as-needed basis, and the need for interferon alfa injections has decreased to every 3 months. The patient has been followed up for 1 year without any recurrence.

Figure 4. 
Complete clinical response to the combination therapy.

Complete clinical response to the combination therapy.


There are many therapeutic modalities that can be used for the treatment of primary cutaneous B-cell lymphoma (CBCL).1-6 Systemic chemotherapy, including cyclophosphamide, doxorubicin, vincristine, and prednisone, as monotherapy or in combination as polychemotherapy, can be used. Fierro et al4 showed that the use of COP (cyclophosphamide, vincristine [Oncovin], prednisone) or CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) polychemotherapy resulted in response rates of 98% with a relapse rate of 33%. Santucci et al7 showed 100% remission rate, with two thirds of the patients having relapses. In a report by Wong and Weller,3 intralesional steroids were shown to be effective in controlling local skin relapses of CBCL. Furthermore, radiation therapy may be successfully combined with chemotherapeutic agents or administered alone. Berti et al8 demonstrated complete remission in 100% of their cases; however, there were a large number of relapses (14/44). Piccinno et al9 also showed 100% complete remission rate with 68% relapse rate. There are also reports of intralesional cisplatin and intralesional interferon alfa as effective therapy. There are a couple of case reports regarding the use of intralesional interferon alfa for CBCL. Santucci et al7 reported that 1 of the 2 patients treated had complete remission. However, the dosage and frequency of treatments were not discussed. Zenone et al5 treated 1 patient who had complete remission with intralesional interferon alfa after failing 5 treatments of polychemotherapy and radiation. For the first 2 months the patient received 3 million units every week, then 5 million units was given every week for 4 months. Finally, the patient received 10 million units every month for 6 months. The patient had no recurrence 1 year after treatment. More recently, systemic and intralesional rituximab, an anti-CD20 monoclonal antibody, has produced excellent response rates. We know of no published reports regarding the treatment of CBCL with Targretin or topical alitretinoin gel (Panretin, Ligand Pharmaceuticals Inc). Therefore, when considering treatment options, it is necessary to select the drug that is safe, effective, and convenient.

The use of bexarotene (Targretin), a retinoid that selectively activates the retinoid X receptors, has been used in the successful treatment of cutaneous T-cell lymphoma (CTCL), has shown substantial results in acquired immunodeficiency syndrome–related Kaposi sarcoma, and has prolonged survival of patients with non–small cell lung carcinoma and advanced renal cell carcinoma (when combined with interferon alfa).10-18 Bexarotene is a member of a class of retinoids that selectively activate the retinoid X receptors. When these receptors are activated, they function as transcription factors that regulate gene expression.10-13 These genes cause apoptosis. Retinoids that activate the retinoid A receptors have been shown to control cell differentiation and proliferation.

Oral bexarotene has been used for the treatment of CTCL. However, its use is accompanied by important adverse effects. Bexarotene use can elevate triglyceride levels, leading to pancreatitis; can cause central hypothyroidism; and can elevate transaminase levels.10,11,13,14 Laboratory evaluation has to be undertaken prior to beginning therapy with bexarotene, then weekly for the first 4 weeks and every 8 weeks thereafter, as long as the laboratory values are stable. Its use is also contraindicated in pregnancy given its teratogenic effects.

Bexarotene has recently become available in gel form. It is the first Food and Drug Administration–approved topical agent for the treatment of refractory CTCL. Phase 1 and 2 trials with stage IA and IIA CTCL yielded complete clearing of 21% of the lesions and at least 50% improvement in 63% of lesions.19,20 In phase 3 clinical trials in patients with refractory or persistent stage IA, IB, and IIA CTCL, the overall response rate was 44% with a complete clearing of the lesions in 8% of the patients.21 When compared with Panretin, alitretinoin (a retinoid that can bind to both the retinoid A and X receptors) in the treatment of stage I CTCL, Targretin had an overall response rate of 77%, while Panretin had an overall response rate of 67%.22 From the standpoint of adverse effects, 97% to 98% of patients participating in the phase 1, 2, and 3 trials reported only pruritus (32%-33%), rash (72%-73%), and pain (22%-24%). It is not necessary to check laboratory values in patients using bexarotene gel because there has been no systemic absorption noted.

Since the patient described herein responded to interferon alfa, but did not have clearing of the lesion, Targretin was added as an adjuvant topical agent. Interferon alfa works through the modification of cytokine expression. Targretin gel may work through apoptosis and other yet to be defined mechanisms. In chronic diseases, oftentimes it is more effective to use complementary combination therapy than monotherapy. Our patient had marked improvement with complete clinical resolution of the lesions on his scalp after the addition of the Targretin gel. While the patient has had a remarkable response, he still requires occasional interferon alfa injections, indicating that neither the Targretin gel nor the interferon alfa alone could control his disease. It would appear, therefore, that the combination can be effective in localized low-grade primary CBCL.

Accepted for publication November 27, 2001.

Corresponding author: Francisco A. Kerdel, BSc, MBBS, University of Miami Department of Dermatology, PO Box 016250, Miami, FL 33136 (e-mail:

Sabroe  RAChild  FJWoolford  AJSpittle  MFRussell-Jones  R Rituximab in cutaneous B cell lymphoma.  Br J Dermatol. 2000;143157- 161Google ScholarCrossref
Heinzerling  LDummer  RKempf  WSchmid  MHBurg  G Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B cell lymphoma.  Arch Dermatol. 2000;136374- 378Google ScholarCrossref
Wong  KCWeller  PA Primary cutaneous B cell lymphoma: outcomes and treatment.  Australas J Dermatol. 1998;39261- 264Google ScholarCrossref
Fierro  MTQuaglino  PSavoia  PVerrona  A Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow up study of 81 patients treated with COP or CHOP.  Leuk Lymphoma. 1998;31583- 588Google Scholar
Zenone  TCatimel  GBarbet  NClavel  M Complete remission of a primary cutaneous B cell lymphoma treated with intralesional recombinant interferon alpha-2a.  Eur J Cancer. 1994;30A246- 247Google ScholarCrossref
Pandolfino  TLSiegel  RSKuzel  TMRosen  STGuitart  J Primary cutaneous B cell lymphoma: review and current concepts.  J Clin Oncol. 2000;182152- 2168Google Scholar
Santucci  MPimpinelli  NArganini  L Primary cutaneous B cell lymphoma: a unique type of low grade lymphoma.  Cancer. 1991;672311- 2326Google ScholarCrossref
Berti  EAlessi  ECaputo  R  et al.  Reticulohistiocytoma of the dorsum.  J Am Acad Dermatol. 1988;19259- 272Google ScholarCrossref
Piccinno  RCaccialanza  MBerti  E  et al.  Radiotherapy of cutaneous B cell lymphomas: our experience in 21 cases.  Int J Radiat Oncol Biol Phys. 1993;27385- 389Google ScholarCrossref
Not Available, Bexarotene (Targretin) for cutaneous T cell lymphoma.  Med Lett Drugs Ther. 2000;4231- 32Google Scholar
Henney  JE New drug for refractory cutaneous T-cell lymphoma.  JAMA. 2000;2831131Google ScholarCrossref
Miller  VABenedetti  FMRigas  JR  et al.  Initial clinical trial of a selective retinoid X receptor ligand, LGD1069.  J Clin Oncol. 1997;15790- 795Google Scholar
Not Available, Bexarotene (Targretin) [package insert].  San Diego, Calif Ligand Pharmaceuticals Inc2000;
Duvic  MCather  JC Emerging new therapies for cutaneous T cell lymphoma.  Dermatol Clin. 2000;18147- 156Google ScholarCrossref
Millikan  LMustafa  MYocum  R RXR-selective oral retinoid bexarotene (Targretin) shows efficacy and safety in AIDS-related Kaposi's sarcoma.  Abstract and poster presented at: Fifth Annual NCI AIDS Malignancy Conference April 23-25, 2001 Bethesda, MdAbstract 53
Wilding  GCarducci  MAHwu  WJAtkins  MBReich  SD A multicenter phase I-II evaluation of oral bexarotene and interferon alpha 2B combination treatment in patients with advanced renal cell carcinoma.  Presented at: Annual Meeting of the American Society of Clinical Oncology 2001 San Francisco, CalifAbstract 763
Rizvi  NHawkins  MJEisenberg  PDYocum  RCReich  SDLigand L1069-20 Working Group, Placebo controlled trial of bexarotene, a retinoid X receptor agonist, as maintanence treatment for patients treated with chemotherapy for advanced non small cell lung cancer.  Clin Lung Cancer. 2001;2210- 215Google ScholarCrossref
Khuri  FRRigas  JRFiglin  RA  et al.  Multi-institution phase I-II trial of oral bexarotene in previously untreated patients with advanced non small cell lung cancer.  J Clin Oncol. 2001;192626- 2637Google Scholar
Breneman  DDuvic  MKuzel  TStevens  VYocum  R Phase I-II clinical trial demonstrates the safety and efficacy of bexarotene (LGD1069) topical gel for the treatment of cutaneous T cell lymphoma.  Abstract presented at: 57th Annual Meeting of the American Academy of Dermatology March 19-24, 1999 New Orleans, La
Kuzel  TBreneman  DDuvic  MTruglia  JYocum  RStevens  V Phase I-II trial of Targretin gel in the topical treatment of patients with cutaneous T cell lymphoma [abstract].  J Inv Dermatol. 2000;114830Google Scholar
Heald  PMehlmauer  MMartin  AOlsen  E  et al.  The benefits of topical bexarotene (Targretin) in patients with refractory or persistent early stage CTCL [abstract].  J Invest Dermatol. 2000;114840Google Scholar
Whaley  KLCather  JWalker  D  et al.  Topical retinoids improve stage I cutaneous T cell lymphoma lesions.  Presented at: Society for Investigative Dermatology April 1997 Washington, DC